Publications

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.

Bello E

Br J Cancer. 2019 Aug 14;121(6):464-473. doi: 10.1038/s41416-019-0550-2

Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.

Cortinovis D

Clin Lung Cancer. 2020 Jul 3;22(4):361-370.e3. doi: 10.1016/j.cllc.2020.06.028

Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis.

Paracchini L

JAMA Netw Open. 2020 Jul 1;3(7):e207566. doi: 10.1001/jamanetworkopen.2020.7566

Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.

Paracchini L

Clin Cancer Res. 2020 Dec 15;27(9):2549-2559. doi: 10.1158/1078-0432.CCR-20-3345

Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy.

Belgiovine C

Eur J Immunol. 2021 Oct 8;51(11):2677-2686. doi: 10.1002/eji.202149379

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment.

Allavena P

Front Oncol. 2022 Mar 1;12:851790. doi: 10.3389/fonc.2022.851790

Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study.

Mannarino L

Int J Mol Sci. 2022 May 21;23(10)doi: 10.3390/ijms23105786

Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis.

Pesenti C

Eur J Cancer. 2022 Jun 14;171:85-95. doi: 10.1016/j.ejca.2022.05.005

Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations.

Mannarino L

Cell Death Dis. 2022 Jul 15;13(7):612. doi: 10.1038/s41419-022-05073-4

Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer.

Paracchini L

Cancers (Basel). 2022 Jul 29;14(15)doi: 10.3390/cancers14153697